Literature DB >> 17906849

[Modern treatment of ankylosing spondylitis].

S Rehart1, F Kerschbaumer, J Braun, J Sieper.   

Abstract

Bechterew's disease belongs to subgroup of spondyloarthritis. Even today there is still a delay of 5-10 years between the first occurrence of symptoms and the final diagnosis of ankylosing spondylitis. Without treatment the spine increasingly stiffens and the peripheral (mostly large) joints are often destroyed by inflammatory processes. Ankyloses of the joints between vertebrae and ribs may cause stiffness of the thorax. As the complaints most often start within the third decade of life and show a chronic progressive course, even young adults often have to deal with a considerable impairment due to pain and stiffness. Thus, early diagnosis is of utmost importance as today treatment with novel drugs is feasible and the TNFalpha inhibitors are particularly effective during the early stages of the disease. All conservative orthopedic measures are used concomitantly. Surgery encompasses the early resection of inflamed mucosa in joints. In later stages of the disease reconstructive methods, i.e. prosthetics are often applied. Spondylodesis to erect the body, necessary in the end stage of the disease, is beneficial, but elaborate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906849     DOI: 10.1007/s00132-007-1154-8

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  17 in total

Review 1.  The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?

Authors:  Martin Rudwaleit; Muhammad A Khan; Joachim Sieper
Journal:  Arthritis Rheum       Date:  2005-04

2.  [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].

Authors:  B Manger; H Michels; H G Nüsslein; M Schneider; J Sieper
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

3.  The outcome of ankylosing spondylitis: a study of 100 patients.

Authors:  J T Gran; J F Skomsvoll
Journal:  Br J Rheumatol       Date:  1997-07

Review 4.  Ankylosing spondylitis and bowel disease.

Authors:  Martin Rudwaleit; Dominique Baeten
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-06       Impact factor: 4.098

Review 5.  [Imaging in ankylosing spondylitis].

Authors:  J Braun; M Rudwaleit; K G Hermann; R Rau
Journal:  Z Rheumatol       Date:  2007-03       Impact factor: 1.372

6.  Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging.

Authors:  M Bollow; T Fischer; H Reisshauer; M Backhaus; J Sieper; B Hamm; J Braun
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

Review 7.  Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.

Authors:  Arthur Kavanaugh; Zuhre Tutuncu; Teresa Catalan-Sanchez
Journal:  Curr Opin Rheumatol       Date:  2006-07       Impact factor: 5.006

8.  Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors.

Authors:  S Brophy; S Pavy; P Lewis; G Taylor; L Bradbury; D Robertson; C Lovell; A Calin
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

Review 9.  Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials.

Authors:  Junmin Chen; Chao Liu
Journal:  J Rheumatol       Date:  2006-04       Impact factor: 4.666

10.  Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Authors:  M Rudwaleit; J Listing; J Brandt; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-03-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.